World Health Organization : Year 1998 ; The Special Programme for Research and Training in Tropical Diseases Er Rd, No. 98.4: TDR’s Contribution to the Development of the Fumigant Canister for Controlling Chagas Disease

By Michael. Reich

Book Id: WPLBN0000152242
Format Type: PDF eBook
File Size: 1.3 MB
Reproduction Date: 2005

Title:	World Health Organization : Year 1998 ; The Special Programme for Research and Training in Tropical Diseases Er Rd, No. 98.4: TDR’s Contribution to the Development of the Fumigant Canister for Controlling Chagas Disease
Author:	Michael. Reich
Volume:
Language:	English
Subject:	Health., Public health, Wellness programs
Collections:	Medical Library Collection, World Health Collection
Historic Publication Date:
Publisher:	World Health Organization


Citation APA MLA Chicago Reich, M. (n.d.). World Health Organization : Year 1998 ; The Special Programme for Research and Training in Tropical Diseases Er Rd, No. 98.4. Retrieved from http://gutenberg.cc/

Description
Medical Reference Publication

Excerpt
Purpose of report This report examines how the UNDPlWorld BanklWHO Special Programme for Research and Training in Trupical Diseases (TDR) contributcd to the development of multidmg therapy for leprosy, a treaiment strategy based on combined drugs that has drarnatically reduced the prevalence of the disease worldwide. In particular, the report aims to identify: The Programme's major contributions to WHO'S initial decision to recommend multidmg therapy (MDT) and to the development of the standard treatment regimen; . Factors that enhanced or limited TDR's contributions; and . Implications of these findings for TDR's mandate in dmg development for tropical diseases. Following a brief introduction to leprosy, the report is strücnired in four parts. First, the problems with treaunent that prompted WHO to recommend MDT are described. Second, the report describes the development and implementation of the treamnt, identifying the roles of TDR and other major actors.

Table of Contents
Table of contents Page Purpose of report . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3 Introduction to leprosy . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 5 1 . Problems of treatlng leprosy . . . . . . . . . . . . . . . . . . . . . . . . . . . . 7 1.1 Detection of Mycobacterium leprae . . . . . . . . . . . . . . . . . . . . . . . . . . 7 1.2 Drug treatrnent . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 8 1.3 Prevention . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .1.0 1.4 Available resources . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .1.0 1.5 Conclusion . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .1.1 2 . Development of MDT strategy . . . . . . . . . . . . . . . . . . . . . . . . . 13 2.1 Priorities and strategies set by TDR . . . . . . . . . . . . . . . . . . . . . . . . . . 1.3 2.2 Decision to recommend MDT . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .1 4 2.3 Financial appropriations . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .17 2.4 Support to endemic countries . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .18 2.5 Production, procurement and distribution of standard MDT . . . . . . . . . . .1 9 2.6 Implernentation of MDT programs . . . . . . . . . . . . . . . . . . . . . . . . . . . 20 2.7 Piicing of standard MDT . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .2 0 3 . Impact of MDT on global leprosy burden . . . . . . . . . . . . . . . . . . 21 4 . TDR's achievements and lessons for the future . . . . . . . . . . . . . . . 23 4.1 Epiderniological surveillance . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .2 3 4.2 Clinical trials . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .2.3 4.3 Laboratory studies . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .25 Conclusions . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 27 Annex I : List of tables . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 31 Annex 2: List of people interviewed . . . . . . . . . . . . . . . . . . . . . . . . 37 Amex 3: Methodology . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 41